SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA classifies Cipla’s Bengaluru manufacturing facility as Voluntary Action Indicated

10 Feb 2025 Evaluate

United States Food and Drugs Administration (USFDA) has classified routine current Good Manufacturing Practices (cGMP) inspection conducted at Cipla’s Bengaluru manufacturing facility, as Voluntary Action Indicated (VAI). USFDA had conducted routine current Good Manufacturing Practices inspection at Cipla’s said facility from November 07 to November 13, 2024. 

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1228.90 -9.40 (-0.76%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×